

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

*(Use as many sheets as necessary)*

**Complete if Known**

Application Number	10/817,058
Filing Date	April 2, 2004
First Named Inventor	John E. Baker, Ph.D.
Art Unit	<del>1614</del> 1653
Examiner Name	Unknown
Attorney Docket Number	BA-32448(1)

Sheet	1	of	5
-------	---	----	---

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS


[illegible]

Examiner Signature	<i>August M. Walker</i>	Date Considered	19 October 2001
-----------------------	-------------------------	--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**



PTO/SB/08B (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/817,058
		Filing Date	April 2, 2004
		First Named Inventor	John E. Baker, et al.
		Art Unit	<del>Unknown</del> 1614 1653
		Examiner Name	Unknown
Sheet 2 of 5	Attorney Docket Number	BA-32448(1)	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
mm		Hoffman, 2000 "Incidence, prevalence, and inheritance of congenital heart disease." In J. Moller, and J. Hoffman (eds.), Pediatric Cardiovascular Medicine: 257-262. New York: Churchill Livingstone.	
		Baker et al., 1995, "Tolerance of the developing heart to ischemia: impact of hypoxemia from birth", Am. J. Physiol. 268:H1165-1173.	
		Rafiee et al., 2002, "Activation of protein kinases in chronically hypoxic infant human and rabbit hearts: role in cardioprotection", Circulation 106:239-245.	
		Shi et al., 2000, "Chronic myocardial hypoxia increases nitric oxide synthase and decreases caveolin-3." Free Radic. Biol. Med. 29:695-703.	
		Baker et al., 1997, "KATP channel activation in a rabbit model of chronic myocardial hypoxia", J Mol Cell Cardiol 29:845-848.	
		Baker et al., 1997, "Increased tolerance of the chronically hypoxic immature heart to ischemia. Contribution of the KATP channel", Circulation 95:1278-1285.	
		Nagata et al., 1998, "Activation of p38 MAP kinase and JNK but not ERK is required for erythropoietin-induced erythroid differentiation", Blood 92:1859-1869.	
		Siren et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress", Proc. Natl. Acad. Sci. U.S.A. 98:4044-4049.	
		Baker et al., 1999, "Preconditioning in immature rabbit hearts: role of KATP channels", Circulation 99:1249-1254.	
		Xu et al., 2002, "Cytoprotective role of Ca <sup>2+</sup> - activated K <sup>+</sup> channels in the cardiac inner mitochondrial membrane", Science 298:1029-1033.	

Examiner Signature	<i>Susan M. Mayer</i>	Date Considered	21 October 2004
--------------------	-----------------------	-----------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**Complete if Known**

Application Number	10/817,058
Filing Date	April 2, 2004
First Named Inventor	John E. Baker, et al.
Art Unit	Unknown <del>1614</del> 1653
Examiner Name	Unknown
Attorney Docket Number	BA-32448(1)

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet **3** of **5**

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
Emm		Walker et al., 2000, "Nitric oxide-dependent pulmonary vasodilation in polycythemic rats", Am. J. Physiol. Heart Circ. Physiol. 279:H2382-2389.	
		Ammarguella et al., 2001, "Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells", Biochem. Biophys. Res. Commun. 284:1031-1038.	
		Devery et al., 1997, "Activation of Raf-1 and mitogen-activated protein kinases by erythropoietin and inositolphosphate-glycan in normal erythroid progenitor cells: involvement of protein kinase C." Cell Signal 9:41-46.	
		Gross. 2000, "The role of mitochondrial KATP channels in cardioprotection", Basic Res Cardiol 95:280-284.	
		Sato et al., 2000, "The role of mitochondrial K(ATP) channels in cardioprotection", Basic Res Cardiol 95:285-289.	
		Eells et al., 2000, "Increased mitochondrial K(ATP) channel activity during chronic myocardial hypoxia. Is cardioprotection mediated by improved bioenergetics?" Circ Res 87:91	
		Suzuki et al., 2003, "Cardioprotective effect of diazoxide is mediated by activation of sarcolemmal but not mitochondrial ATP-sensitive potassium channels in mice", Circulation 107:682-685	
		Zhang et al., 2001, "Characteristics and superoxide-induced activation of reconstituted myocardial mitochondrial ATP-sensitive potassium channels", Circ Res 89:1177-1183.	
		Wu et al., 1999, "Relationship between erythropoietin and nitric oxide in the contraction of rat renal arcuate arteries and human umbilical vein endothelial cells", Clin Sci (Lond) 97:413-419.	
		Digicaylioglu et al., 2001, "Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades", Nature 412:641-647.	

Examiner Signature	<i>Aurane M. Mayer</i>	Date Considered	21 October 2004
--------------------	------------------------	-----------------	-----------------

\*EXAMINER: Initial if referenced considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE          STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/817,058		
		Filing Date	April 2, 2004		
		First Named Inventor	John E. Baker, et al.		
		Art Unit	Unknown <del>1611</del> 1653		
		Examiner Name	Unknown		
Sheet	4	of	5	Attorney Docket Number	BA-32448(1)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
gmm		Siebenlist. 2001, "Signal transduction. Barriers come down", Nature 412:601-602.	
		Jones et al., 2001, "Hypoxic preconditioning induces changes in HIF-1 target genes in neonatal rat brain", J. Cereb. Blood Flow Metab. 21:1105-1114.	
		Parsa et al., 2003, "A novel protective effect of erythropoietin in the infarcted heart", J Clin Invest 112:999-1007.	
		Cai et al., 2003, "Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury", Circulation 108:79-85.	
		Clements-Jewery et al., 2002, "Independent contribution of catecholamines to arrhythmogenesis during evolving infarction in the isolated rat heart", Br J Pharmacol 135:807-815	
		Farkas et al., 2002, "Limited antifibrillatory effectiveness of clinically relevant concentrations of class I antiarrhythmics in isolated perfused rat hearts", J Cardiovasc Pharmacol 39:412-424.	
		Baker et al., 2000, "Resistance to myocardial ischemia in five rat strains: is there a genetic component of cardioprotection?" Am. J. Physiol. Heart Circ. Physiol. 278:H1395-1400.	

Examiner Signature	<i>Suzanne M. Mayer</i>	Date Considered	21 October 2001
--------------------	-------------------------	-----------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/817,058
		Filing Date	April 2, 2004
		First Named Inventor	John E. Baker, Ph.D.
		Art Unit	<del>1614</del> 1653
Examiner Name	Unknown		
Attorney Docket Number	BA-32448(1)		
Sheet	5 of 5		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	r2
Smul		Cody et al., Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patents (Cochrane Review), from <i>The Cochrane Library</i> , Issue 1, 2004, Chichester, UK: John Wiley & Sons, Ltd. ( <a href="http://www.update-software.com/abstracts/AB003895.html">www.update-software.com/abstracts/AB003895.html</a> )	
		Parsa et al., A novel protective effect of erythropoietin in the infarcted heart, <i>J. Clin. Invest.</i> 112(7): 999-1007 (Oct. 2003)	
		Ravingerovia et al., Preconditioning Modulates Susceptibility to Ischemia-induced Arrhythmias in the Rat Heart: The Role of $\alpha$ -Adrenergic Stimulation and K (ATP) Channels, <i>Physiol. Res.</i> 51: 109-119 (2002)	
		Shi et al., Acute Cardioprotective Effects of Erythropoietin are Mediated by Activation of Protein Kinases and Potassium Channels, <i>Circulation</i> (Supp. IV) 108 (17): Abstract 1299 (Oct. 28, 2003)	
		Shi et al., Acute Cardioprotective Effects of Erythropoietin in Infant Rabbits are Mediated by Activation of Protein Kinases and Potassium Channels, <i>Basic Res. Cardiol.</i> 99: 1-10 (Published on line Jan. 29, 2004)	
		Cody et al., Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients (Cochrane Review), , from <i>The Cochrane Library</i> , Issue 1, 2004, Chichester, UK: John Wiley & Sons, Ltd. ( <a href="http://www.update-software.com/abstracts/AB003266.html">www.update-software.com/abstracts/AB003266.html</a> )	

Examiner  
Signature

*Suzanne M. Mayr*

Date

Considered

21 October 2004

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.